BioSpace News Archive

MDmetrix, a clinical performance management platform, today announced it has developed new control charts that project daily deaths from COVID-19 nationally and by state

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the 2020 Needham Healthcare Conference

electroCore, Inc. announced that England’s National Health Service has exercised its option to extend the Innovation and Technology Payment Program for the use of gammaCore in the treatment of cluster headache in adults.

PRA Health Sciences announced that Symphony Health, a PRA Health Sciences company, will make a 30-day license of its newly released MetysTM COVID-19 Module available to the U.S. life science industry at no charge.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced preliminary first quarter 2020 revenue and provided a business update, including the actions it is taking in response to COVID-19.

Vanda Pharmaceuticals Inc. (“Vanda”) (Nasdaq: VNDA) and the University of Illinois at Chicago (UIC) today announced a research partnership focused on the investigation of small molecules with the potential to treat COVID-19.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that its Board of Directors authorized the adoption of a limited duration rights plan (“Rights Plan”).

Engineered and designed by CRB, Andover Clinical Manufacturing Facility focuses on integration and flexibility to speed patient therapies

The American Diabetes Association (ADA) is pleased to announce that Robert A. Gabbay, MD, PhD has been named Chief Scientific & Medical Officer (CSMO).

Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), announces that at the Corporation’s Annual General Meeting (AGM) held today the Corporation’s shareholders voted to support all of the resolutions that came before the meeting.